Over the next 5 years, Jaleva is well positioned to accelerate its growth as a specialty pharmaceutical company.
The Company is developing a deep pipeline of products that is superior to current leaders in large CNS markets. Superiority in these cases is defined as a faster onset of the medication not provided by current technology.
Its technology can be applied to a number of indications: anti anxiety disorders; antiemesis; migraines; pain and pain management; delivery of hormones and certain steroids; administration of transdermal nicotine to aid in smoking cessation.
We seek to license or partner with a firm that has a desire to market CNS actives with our superior delivery system of the active ingredient.
Our FDA routes are short since we typically enter a marketplace with an active ingredient already approved by the FDA.
Our IP is strong and covers our technology broadly.
